Argos Therapeutics Inc. (NASDAQ:ARGS) shares were up 4.2% on Monday . The company traded as high as $4.97 and last traded at $4.96, with a volume of 146,901 shares changing hands. The stock had previously closed at $4.76.

A number of research analysts have recently weighed in on ARGS shares. Roth Capital raised their target price on Argos Therapeutics from $11.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, April 19th. Zacks Investment Research upgraded Argos Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 target price on the stock in a report on Tuesday, May 17th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $11.00 price target on shares of Argos Therapeutics in a research report on Monday, June 20th. FBR & Co reaffirmed a “buy” rating on shares of Argos Therapeutics in a research report on Tuesday, June 14th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Argos Therapeutics in a research report on Friday, June 17th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Argos Therapeutics has an average rating of “Buy” and an average price target of $11.84.

The company’s market capitalization is $126.87 million. The firm’s 50-day moving average is $5.83 and its 200 day moving average is $5.71.

Argos Therapeutics (NASDAQ:ARGS) last released its quarterly earnings data on Thursday, May 12th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by $0.01. On average, equities analysts anticipate that Argos Therapeutics Inc. will post ($1.68) EPS for the current year.

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.